Table 1 Patient clinical characteristics
N = 34 | |
|---|---|
Gender, n (%) | |
Male | 1 (2.94) |
Female | 33 (97.06) |
Age of pSS onset, median (IQR), years | 33.50 (29.00,38.50) |
Age of PAH onset, median (IQR), years | 34.00 (30.50,41.50) |
Disease duration of pSS at PAH onset, median (IQR), months | 1.00 (1.00,15.50) |
Clinical manifestations of pSS, n (%) | |
Ocular symptoms | 15 (44.12) |
Oral symptoms | 24 (70.59) |
Ocular signs | 28 (82.35) |
Salivary gland involvement | 30 (88.24) |
Histopathology | 14 (41.18) |
Autoantibody positivity, n (%) | |
ANA | 34 (100.00) |
Anti-SSA | 31 (91.18) |
Anti-SSB | 11 (32.35) |
Anti-Ro52 | 28 (82.35) |
Anti-RNP | 6 (17.65) |
Organ involvement, n (%) | |
Hematologic | 6 (17.65) |
Mucocutaneous | 1 (2.94) |
Musculoskeletal | 1 (2.94) |
Gland | 2 (5.88) |
SSDDI, median (IQR) | 1.00 (0.75,2.00) |
WHO cardiac function class, n (%) | |
I | 1 (2.94) |
II | 28 (82.35) |
III | 5 (14.71) |
Family history, n (%) | 7 (20.59) |